Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.77 |
| ▸ | CX3CR1 | P49238 | 16/20 | 0.77 |
| ▸ | HTR1B | P28222 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5483535 | 1.00 | CXCR2 (0.77) | CXCR2CX3CR1HTR1B | |
| SCHEMBL213765 | 0.87 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL5436819 | 0.86 | CXCR2 (1.00) | CXCR2CX3CR1HTR1B | |
| SCHEMBL5484096 | 0.85 | CXCR2 (0.83) | CXCR2CX3CR1HTR1B | |
| SCHEMBL5484101 | 0.85 | CXCR2 (0.83) | CXCR2CX3CR1HTR1B | |
| SCHEMBL23828009 | 0.84 | CXCR2 (0.77) | CXCR2CX3CR1HTR1B | |
| SCHEMBL31199187 | 0.84 | CXCR2 (0.77) | CXCR2CX3CR1HTR1B | |
| SCHEMBL23828012 | 0.84 | CXCR2 (0.77) | CXCR2CX3CR1HTR1B | |
| SCHEMBL5444488 | 0.82 | CXCR2 (0.69) | CXCR2CX3CR1HTR1B | |
| SCHEMBL5237440 | 0.81 | CX3CR1 (1.00) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142386-A1 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 | ASTRAZENECA (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142386-A1 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 | CX3CR1, CCR2, CXCR4 | CXCR2 6/4885CX3CR1 1/4885HTR1B 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.